Direct Protein Delivery to Mammalian Cells Using Cell-permeable Cys2-His2 Zinc-finger Domains

1Departments of Chemistry and Cell and Molecular Biology, The Scripps Research Institute, 2Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University
* These authors contributed equally
Published 3/25/2015
0 Comments
  CITE THIS  SHARE 
Biology

Your institution must subscribe to JoVE's Biology section to access this content.

Fill out the form below to receive a free trial or learn more about access:

Welcome!

Enter your email below to get your free 10 minute trial to JoVE!





By clicking "Submit", you agree to our policies.

 

Summary

Zinc-finger domains are intrinsically cell-permeable and capable of mediating protein delivery into a broad range of mammalian cell types. Here, a detailed step-by-step protocol for implementing zinc-finger technology for intracellular protein delivery is presented.

Cite this Article

Copy Citation

Gaj, T., Liu, J. Direct Protein Delivery to Mammalian Cells Using Cell-permeable Cys2-His2 Zinc-finger Domains. J. Vis. Exp. (97), e52814, doi:10.3791/52814 (2015).

Abstract

Due to their modularity and ability to be reprogrammed to recognize a wide range of DNA sequences, Cys2-His2 zinc-finger DNA-binding domains have emerged as useful tools for targeted genome engineering. Like many other DNA-binding proteins, zinc-fingers also possess the innate ability to cross cell membranes. We recently demonstrated that this intrinsic cell-permeability could be leveraged for intracellular protein delivery. Genetic fusion of zinc-finger motifs leads to efficient transport of protein and enzyme cargo into a broad range of mammalian cell types. Unlike other protein transduction technologies, delivery via zinc-finger domains does not inhibit enzyme activity and leads to high levels of cytosolic delivery. Here a detailed step-by-step protocol is presented for the implementation of zinc-finger technology for protein delivery into mammalian cells. Key steps for achieving high levels of intracellular zinc-finger-mediated delivery are highlighted and strategies for maximizing the performance of this system are discussed.

Introduction

Highly efficient and versatile protein delivery strategies are critical for many basic research and therapeutic applications. The direct delivery of purified proteins into cells represents one of the safest and easiest methods for achieving this.1,2 Unlike strategies that rely on gene expression from nucleic acids,3-5 protein delivery poses no risk of insertional mutagenesis, is independent of the cellular transcription/translation machinery and allows for an immediate effect. However, the lack of simple and generalizable methods for endowing cell-penetrating activity onto proteins routinely confounds their direct entry into cells. Current methods for facilitating intracellular protein delivery are based on the use of naturally occurring6-8 or designed cell-penetrating peptides,9-12 supercharged transduction domains,13,14 nanoparticles15 and liposomes,16 virus-like particles17,18 and polymeric microsphere materials.19 Unfortunately, many of these approaches are hampered by low cellular uptake rates,20,21 poor stability,22 inadvertent cell-type specificity,23 low endosomal escape properties24 and toxicity.25 In addition, many protein transduction technologies reduce the bioactivity of the delivered proteins.14

Our laboratory previously demonstrated that zinc-finger nuclease (ZFN) proteins — chimeric restriction endonucleases consisting of a programmable Cys2-His2 zinc-finger DNA-binding protein and the cleavage domain of the FokI restriction endonuclease26-28 — are inherently cell-permeable.29 This surprising cell-penetrating activity was shown to be an intrinsic property of the custom-designed zinc-finger domain, a DNA-binding platform that has emerged as a powerful tool for targeted genome engineering,30-32 and considered to be the result of the constellation of six positively charged residues on the protein surface. Indeed, several DNA-binding proteins, including c-Jun and N-DEK have been shown to possess an innate capacity to cross cell membranes.33 More recently, our laboratory expanded on these results and demonstrated that the cell-penetrating activity of zinc-finger (ZiF) domains could be leveraged for intracellular protein delivery. Genetic fusion of either one- or two-finger ZiF domains to specific protein cargo led to uptake efficiencies that exceeded many conventional cell-penetrating peptide delivery systems.34 Most notably, ZiF-mediated delivery did not compromise the activity of fused enzymatic cargo and facilitated high levels of cytosolic delivery. Collectively, these findings demonstrate the potential of the ZiF domain for facilitating the efficient and facile delivery of proteins, and potentially more diverse types of macromolecules, into cells.

Here, a detailed step-by-step protocol on how to implement ZiF technology for protein delivery in mammalian cells is presented. We previously constructed a suite of one-, two-, three-, four-, five- and six-finger ZiF domains that lack the ability to bind DNA, due to substitution of each of the α-helical DNA-binding residues, but are capable of delivering proteins into cells34 (Figure 1). The production and transduction of Emerald GFP (EmGFP) into HeLa cells using a two-finger ZiF domain is described. This protocol is extensible to almost any protein capable of soluble expression in Escherichia coli and nearly any mammalian cell type. Expected results are provided and strategies for maximizing the performance of this system are also discussed.

Subscription Required. Please recommend JoVE to your librarian.

Protocol

1. Cloning

  1. Obtain alanine-substituted two-finger ZiF domains that have been sub-cloned into the pET-28 expression vector system and are available upon request (pET-2F-ZiF).34
  2. PCR amplify EmGFP from the plasmid Emerald-pBAD with the primers 5’ XmaI-EmGFP (5’-GGAAATTGCCCGGGATGGTGAGCAAGGGCGAGGAGCTGTTCAC-3’; XmaI site in bold) and 3’ SacI-EmGFP (5’-CGGATCTGAGCTCTTACTTGTACAGCTCGTCCATGCCGAG-3’; SacI site in bold).
    1. Use 5 ng of template DNA, 10 μl of 10x polymerase buffer, 1 Units (U) of Taq DNA polymerase, 0.2 mM each dNTP and 0.2 μM of each primer in a 100 μl solution with the remaining volume made up of distilled/deionized water. Use the cycling conditions: 95 °C for 5 min; 30 cycles of 95 °C for 30 sec, 55 °C for 30 sec and 72 °C for 1 min; 72 °C for 10 min. Purify the PCR product by gel extraction and determine DNA concentration using a spectrophotometer measuring Abs260 x 50 μg/ml.
  3. Digest pET-2F-ZiF and the insert encoding EmGFP with the restriction enzymes XmaI and SacI in recommended buffer for 3 hr at 37 °C using 10 U of enzyme per 1 μg of DNA. Visualize DNA by agarose gel electrophoresis using a fluorescent intercalating dye, such as ethidium bromide.
  4. Purify the digested DNA by gel extraction kit and determine DNA concentration by a spectrophotometer measuring Abs260 x 50 μg/ml.
  5. Ligate the purified EmGFP-encoding DNA into 50-100 ng of pET-2F-ZiF using 1 U of T4 DNA Ligase for at least 1 h at RT For best results, perform the ligation reaction using a 6:1 insert-to-vector molar ratio.
  6. Thaw 50 μl of any chemically competent XL-1 Blue Escherichia coli cells on ice and mix gently with 10-20 ng of ligated pET-2F-ZiF-EmGFP.
  7. Keep on ice for 30 min. Heat shock the mixture at 42 °C for 90 sec and recover the cells in 2 ml of Super Optimal broth with Catabolite repression (SOC) for 1 hr at 37 °C with shaking.
  8. Spread 100 μl of recovery culture on a lysogeny broth (LB) agar plate with 50 μg/ml kanamycin and incubate O/N at 37 °C.
  9. The following day, inoculate 6 ml of Super Broth (SB) or LB culture containing 50 μg/ml kanamycin with one colony from the LB agar plate and culture O/N at 37 °C.
    Note: Colony PCR using the primers 5’ XmaI-EmGFP and 3’ SacI-EmGFP could be used to identify positive clones prior to miniprep.
  10. Purify pET-2F-ZiF-EmGFP by miniprep and confirm plasmid by DNA sequencing using T7 promoter (5’-TAATACGACTCACTATAGGG-3’).

2. Expression and Purification

  1. Thaw 50 μl of chemically competent BL21 E. coli cells on ice and mix gently with 100 ng of pET-2F-ZiF-EmGFP plasmid. Transform as described in steps 1.7-1.8.
  2. The following day, inoculate 10 ml of LB medium containing 50 μg/ml kanamycin with a single colony and grow O/N at 37 °C with shaking.
  3. The following day, dilute the 10 ml of O/N culture into 1 L of LB medium supplemented with 50 μg/ml kanamycin, 0.2% glucose and 100 μM ZnCl2. Grow the culture at 37 °C with shaking to an optical density at 600 nm (OD600) of 0.8 and induce protein expression with 2 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG). After 6 hr of growth at 37 °C, harvest cells by centrifugation at 5,000 x g for 10 min at 4 °C.
    Note: Induction conditions are highly variable and depend on the stability of the proteins being expressed. Monitor the OD600 every 30 min until an OD600 of 0.8 is reached.
  4. Resuspend the cell pellet in 5 ml of lysis buffer (50 mM Tris-HCl, 500 mM NaCl, 100 μM ZnCl2, 1 mM dithiothreitol (DTT), 1 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride (PMSF) and 10 mM imidazole, pH 8.0). Lyse the cells on ice by sonication with the following setting: 50% power output, 4 min process time with 5 sec on/10 sec off intervals. Avoid overheating the solution.
  5. Centrifuge the cell lysate at 25,000 x g for 30 min at 4 °C and transfer the supernatant into a fresh collection tube. For best results, perform all the following steps at 4 °C.
  6. Run the supernatant through a column pre-packed with 1 ml of equilibrated Ni-NTA slurry. Wash the resin with 20 ml of wash buffer (50 mM Tris-HCl, 500 mM NaCl, 100 μM ZnCl2, 1 mM DTT, 1 mM MgCl2 and 30 mM imidazole, pH 8.0).
  7. Elute the protein with 5 ml of elution buffer (50 mM Tris-HCl, 500 mM NaCl, 100 μM ZnCl2, 1 mM DTT, 1 mM MgCl2, and 300 mM imidazole, pH 8.0).
  8. Buffer exchange the eluted protein with storage buffer (50 mM Tris-HCl, 500 mM NaCl, 100 μM ZnCl2, 1 mM DTT, 1 mM MgCl2 and 10% glycerol, pH 8.0) and concentrate the protein to at least 40 μM using a spin concentrator by centrifugation according to the manufacturer’s instructions.
  9. Determine protein concentration by BCA or Bradford assay. Mix 2 μl of purified proteins with 2 μl 2× SDS-PAGE loading dye, boil at 95 °C for 10 min and then resolve on 4%-20% Tris-Glycine SDS-PAGE to assess protein purity (Figure 2).

3. Protein Storage

  1. Aliquot the concentrated protein, flash freeze in liquid nitrogen and store at -80 °C. For EmGFP fusion proteins, cover the tube with aluminum foil in order to protect the protein from light.
  2. Avoid repeated freezing and thawing of the protein solution. Note: ZiF-fused proteins are stable under these conditions for at least 1 month. Inappropriate or >4 month storage may lead to protein precipitation or photobleaching of EmGFP.

4. Protein Transduction

  1. Maintain HeLa cells in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS) and 1% antibiotic-antimycotic at 37 °C in a fully humidified atmosphere with 5% CO2.
    Note: Cells passaged more than 30 times are not recommended for protein transduction.
  2. Pre-coat a 24-well plate with 500 μl of 50 μg/ml of poly-lysine for 30 to 60 min at 25 °C. Seed cells onto a 24-well plate at a density of 2 × 105 cells per well. At 24 hr after seeding, or once cells are between 80%-90% confluent, remove media from each well and wash with 500 μl of pre-warmed serum-free DMEM (SFM).
  3. To each well, add 250 μl of SFM containing 2 μM of ZiF-EmGFP protein and 100 μM ZnCl2. Incubate cells at 37 °C for 1 hr. Note: ZiF domains enter cells primarily through macropinocytosis,34 which is an energy-dependent mechanism. Therefore, cells must be incubated at 37 °C for efficient protein internalization.
  4. Remove media from cells and wash three times with 500 μl of calcium- and magnesium-free Dulbecco’s phosphate-buffered saline (DPBS) supplemented with 0.5 mg/ml of heparin. Note: Heparin is necessary to remove surface-bound protein that might complicate downstream analyses.
  5. (Optional) Repeat treatments up to three times for enhanced delivery.
  6. Isolate treated cells immediately after heparin wash by digestion with 0.05% trypsin-EDTA at 37 °C for 2 min. Re-suspend detached cells in 0.5 ml of DPBS supplemented with 1% FBS.
  7. Measure the fluorescence intensity of each sample by flow cytometry35 using the fluorescein isothiocyanate (FITC) channel (Figure 3). Adjust the forward scatter (FSC) and side scatter (SSC) to place the population of interest on scale, ensuring that populations with different properties are resolved from each other.
  8. Collect 10,000 live events for each sample and analyze the data using flow cytometry data analysis software.36 Normalize fluorescence from HeLa cells treated with ZiF-EmGFP to those cells treated only with SFM.

Subscription Required. Please recommend JoVE to your librarian.

Representative Results

Two-finger ZiF-EmGFP fusion proteins can be expressed in E. coli with >95% homogeneity and high yields (>25 mg/ml) (Figure 2). In general, one- and two-finger ZiF fusion proteins can be produced in quantities nearly identical to those of wild-type unmodified protein. However, in some contexts, five- and six-finger ZiF fusion proteins are unable to be produced in yields high enough for downstream applications.

Direct application of two-finger ZiF-EmGFP protein onto HeLa cells for 90 min at 37 °C leads to a dose-dependent increase in EmGFP fluorescence (Figure 3A). Critically, no fluorescence is observed in the absence of the ZiF domain. We previously observed that nearly 100% of cells are fluorescent after treatment with only 2 μM of two-finger ZiF-EmGFP protein, and that HeLa cells treated with ZiF fusion protein are positive for EmGFP fluorescence at protein concentrations as low as 0.25 μM (Figure 3B).

Figure 1
Figure 1. Structure and sequence of zinc-finger protein. (Top) Crystal structure of a single zinc-finger (ZiF) domain. The side chains of the conserved Cys and His residues coordinated with the Zn2+ ion are shown as sticks (PDB ID: 2I13).37 (Bottom) Sequence of the ZiF domain. Arrows and cylinders indicate Β-sheet and α-helix secondary structures, respectively. The α-helical DNA-binding residues that have been substituted with alanine are highlighted pink. Positively charged residues predicted to mediate cell internalization are highlighted light blue. Please click here to view a larger version of this figure.

Figure 2
Figure 2. SDS-PAGE of purified one-, two-, three- and four-finger ZiF-EmGFP fusion proteins. ZiF-EmGFP fusion proteins were expressed in E. coli and purified by Ni-NTA agarose resin. Eluted protein was analyzed for purity by SDS-PAGE using a 4%-20% Tris-Glycine gel. No significant degradation or truncations of ZiF-EmGFP fusion proteins was observed.

Figure 3
Figure 3. ZiF-mediated protein delivery into HeLa cells. (A) Fluorescence intensity of HeLa cells treated with increasing amounts of two-finger ZiF-EmGFP protein. HeLa cells treated with EmGFP protein alone overlap entirely with untreated cells. (B) Normalized fluorescence intensity of HeLa cells treated consecutively with 2 μM of two-finger ZiF-EmGFP protein. Fluorescence intensity was determined by flow cytometry.

Subscription Required. Please recommend JoVE to your librarian.

Discussion

Here, a step-by-step protocol for protein delivery using cell-permeable zinc-finger (ZiF) domains is presented. The ZiF domain does not reduce the activity of fused enzymatic cargo34; allows for the production and purification of proteins in yields nearly identical to those observed with unmodified protein; and can transport proteins and enzymes into a wide range of cell types with efficiencies that exceed traditional cell-penetrating peptide or protein transduction domain systems. Together, these findings indicate the broad potential of ZiF domains for mediating direct protein delivery into cells for a wide range of applications.

Maximum protein delivery was previously achieved using only a two-finger ZiF domain, despite the fact that extended arrays of three- and four-finger ZiF domains carry greater positive charge. These findings indicate that ZiF-mediated cell entry might be influenced by factors other than charge, including protein stability or conformational rigidity. ZiF domain-mediated protein delivery was also found to be energy-dependent and thus requires that all cells treated with protein be incubated at 37 °C. Through the usage of small molecule inhibitors of various endocytic pathways, macropinocytosis, and to a lesser extent caveolin-dependent endocytosis, were determined to be the major pathways for ZiF-mediated cell entry.34 Notably, unlike other protein transduction systems, ZiF domains are capable of efficiently escaping endosomes to mediate high levels of cytosolic delivery of the fused macromolecular cargo, underscoring the potential of these domains for achieving robust protein delivery.

In our experience, the seeding density of cells is a critical step for achieving high levels of protein transduction. We recommend treating cells once they reach 80%-90% confluency and previously observed that cells seeded at >95% confluency show sub-optimal transduction capacity, while cells seeded at low densities (<50%) are susceptible to protein-induced toxicity. Importantly, for cell types with high detachment tendencies, cell culture plates pre-coated with poly-lysine are recommended. Poly-lysine facilitates cell attachment through electrostatic interactions with negatively charged cell-surface components. Although the α-helical DNA-binding residues of each ZiF domain have been removed to eliminate any potential for DNA recognition, the cysteine and histidine residues that coordinate with the Zn2+ ion to stabilize the ΒΒα ZiF domain fold remain intact. Thus, we recommend that any storage buffer be supplemented with at least 100 μM of ZnCl2 to maintain protein integrity.

Although the ZiF domain was previously shown to deliver proteins and enzymes into a variety of cell types, the efficiency of ZiF delivery might also be dependent on the both macromolecular cargo and protein concentration. For instance, cells treated with two-finger ZiF-luciferase fusion protein were observed to display maximum luminescence when treated with 0.5 μM protein, with decreased activity at higher concentrations, while cells treated with two-finger EmGFP exhibited a dose-dependent increase in fluorescence intensity up to 8.0 μM protein, and upon consecutive protein treatments. We therefore recommend evaluating the cell penetrating ability of each unique ZiF domain fusion across a range of concentrations.

Finally, although not yet demonstrated, we anticipate that ZiF domain delivery is a highly flexible platform, capable of delivering a diverse array of macromolecules into cells. For example, it may be possible for both DNA and RNA to be chemically functionalized onto the surface of the ZiF domain via a hydrolyzable linker, or transiently transfected into cells by encapsulation of ZiF domains. Additionally, the efficiency of ZiF protein delivery could be further enhanced by rational design efforts focused on surface charge optimization.

Subscription Required. Please recommend JoVE to your librarian.

Disclosures

The authors have nothing to disclose.

Acknowledgements

This work was supported by the National Institutes of Health (DP1CA174426 to Carlos F. Barbas) and ShanghaiTech University, Shanghai, China (to J.L). Molecular graphics were generated using PyMol.

Materials

Name Company Catalog Number Comments
XmaI New England Biolabs R0180L
SacI New England Biolabs R0156L
Expand High Fidelity PCR system Roche 11759078001
dNTPs New England Biolabs N0446S
4%-20% Tris-Glycine Mini protein gels, 1.5 mm, 10 wells Life Technologies EC6028BOX
2x Laemmli Sample Buffer BioRad 161-0737
T4 DNA Ligase Life Technologies 15224-017
BL21 (DE3) Competent E. coli New England Biolabs C2527I
IPTG Thermo Scientific R0391
Zinc Chloride Sigma-Aldrich 208086-5G
Kanamycin Sulfate Fisher Scientific BP906-5
Glucose Sigma-Aldrich G8270-100G
Tris Base Fisher Scientific BP152-25
Sodium Chloride Sigma-Aldrich S9888-25G
DTT Fisher Scientific PR-V3151 
PMSF Thermo Scientific 36978
Ni-NTA Agarose Resin QIAGEN 30210
Glycerol Sigma-Aldrich G5516-500ML
Imidazole Sigma-Aldrich I5513-25G
Amicon Ultra-15 Centrifugal Filter Units EMO Millipore UFC900324
DMEM Life Technologies 11966-025
Fetal Bovine Serum Life Technologies 10437-028
Antibiotic-Antimycotic  Life Technologies 15240-062
24-Well Flat Bottom Plate Sigma-Aldrich CLS3527-100EA
Poly-Lysine Sigma-Aldrich P7280
DPBS, No Calcium, No Magnesium Life Technologies 21600010
Heparan Sulfate Sigma-Aldrich H4777
Trypsin Life Technologies 25300054
HeLa cells ATCC CCL-2
Nano Drop ND-1000 spectrophotometer  Thermo Fisher Scientific
QIAquick PCR Purification Kit QIAGEN 28104
QIAquick Gel Extraction Kit QIAGEN 28704

DOWNLOAD MATERIALS LIST

References

  1. Berg, A., Dowdy, S. F. Protein transduction domain delivery of therapeutic macromolecules. Curr. Opin. Biotechnol. 22, 888-893 (2011).
  2. Lindsay, M. A. Peptide-mediated cell delivery: application in protein target validation. Curr. Opin. Pharmacol. 2, 587-594 (2002).
  3. Luo, D., Saltzman, W. M. Synthetic DNA delivery systems. Nat. Biotechnol. 18, 33-37 (2000).
  4. Guo, X., Huang, L. Recent advances in nonviral vectors for gene delivery. Acc. Chem. Res. 45, 971-979 (2012).
  5. Thomas, C. E., Ehrhardt, A., Kay, M. A. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4, 346-358 (2003).
  6. Frankel, A. D., Pabo, C. O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 55, 1189-1193 (1988).
  7. Elliott, G., O'Hare, P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell. 88, 223-233 (1997).
  8. Derossi, D., Joliot, A. H., Chassaing, G., Prochiantz, A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269, 10444-10450 (1994).
  9. Smith, B. A., et al. Minimally cationic cell-permeable miniature proteins via alpha-helical arginine display. J. Am. Chem. Soc. 130, 2948-2949 (2008).
  10. Daniels, D. S., Schepartz, A. Intrinsically cell-permeable miniature proteins based on a minimal cationic PPII motif. J. Am. Chem. Soc. 129, 14578-14579 (2007).
  11. Karagiannis, E. D., et al. Rational design of a biomimetic cell penetrating peptide library. ACS Nan. 7, 8616-8626 (2013).
  12. Gao, S., Simon, M. J., Hue, C. D., Morrison, B., 3r,, Banta, S. An unusual cell penetrating peptide identified using a plasmid display-based functional selection platform. ACS Chem. Biol. 6, 484-491 (2011).
  13. Fuchs, S. M., Raines, R. T. Arginine grafting to endow cell permeability. ACS Chem. Biol. 2, 167-170 (2007).
  14. Cronican, J. J., et al. Potent delivery of functional proteins into mammalian cells in vitro and in vivo using a supercharged protein. ACS Chem. Biol. 5, 747-752 (2010).
  15. Panyam, J., Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55, 329-347 (2003).
  16. Zelphati, O., et al. Intracellular delivery of proteins with a new lipid-mediated delivery system. J. Biol. Chem. 276, 35103-35110 (2001).
  17. Kaczmarczyk, S. J., Sitaraman, K., Young, H. A., Hughes, S. H., Chatterjee, D. K. Protein delivery using engineered virus-like particles. Proc. Natl. Acad. Sci. U. S. A. 108, 16998-17003 (2011).
  18. Voelkel, C., et al. Protein transduction from retroviral Gag precursors. Proc. Natl. Acad. Sci. U. S. A. 107, 7805-7810 (2010).
  19. Sinha, V. R., Trehan, A. Biodegradable microspheres for protein delivery. J. Control Release. 90, 261-280 (2003).
  20. Liu, J., Gaj, T., Patterson, J. T., Sirk, S. J., Barbas, C. F. 3rd Cell-penetrating peptide-mediated delivery of TALEN proteins via bioconjugation for genome engineering. PLoS One. 9, e85755 (2014).
  21. Ramakrishna, S., et al. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res. 24, 1020-1027 (2014).
  22. Fuchs, S. M., Raines, R. T. Polyarginine as a multifunctional fusion tag. Protein Sci. 14, 1538-1544 (2005).
  23. Mai, J. C., Shen, H., Watkins, S. C., Cheng, T., Robbins, P. D. Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. J. Biol. Chem. 277, 30208-30218 (2002).
  24. Al-Taei, S., et al. Intracellular traffic and fate of protein transduction domains HIV-1 TAT peptide and octaarginine. Implications for their utilization as drug delivery vectors. Bioconjug. Chem. 17, 90-100 (2006).
  25. Jones, S. W., et al. Characterisation of cell-penetrating peptide-mediated peptide delivery. Br. J. Pharmacol. 145, 1093-1102 (2005).
  26. Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., Gregory, P. D. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 11, 636-646 (2010).
  27. Carroll, D. Genome engineering with zinc-finger nucleases. Genetics. 188, 773-782 (2011).
  28. Guo, J., Gaj, T., Barbas, C. F. 3rd, 3rd, Directed evolution of an enhanced and highly efficient FokI cleavage domain for zinc finger nucleases. J. Mol. Biol. 400, 96-107 (2010).
  29. Gaj, T., Guo, J., Kato, Y., Sirk, S. J., Barbas, C. F. 3rd Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat. Methods. 9, 805-807 (2012).
  30. Gersbach, C. A., Gaj, T., Barbas, C. F. 3rd, 3rd, Synthetic zinc finger proteins: the advent of targeted gene regulation and genome modification technologies. Acc. Chem. Res. 47, 2309-2318 (2014).
  31. Gaj, T., Gersbach, C. A., Barbas, C. F. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31, 397-405 (2013).
  32. Perez-Pinera, P., Ousterout, D. G., Gersbach, C. A. Advances in targeted genome editing. Curr. Opin. Chem. Biol. 16, 268-277 (2012).
  33. Cronican, J. J., et al. A class of human proteins that deliver functional proteins into mammalian cells in vitro and in vivo. Chem. Biol. 18, 833-838 (2011).
  34. Gaj, T., Liu, J., Anderson, K. E., Sirk, S. J., Barbas, C. F., 3rd, Protein delivery using Cys2-His2 zinc-finger domains. ACS Chem. Biol. 9, 1662-1667 (2014).
  35. Radcliff, G., Jaroszeski, M. J. Basics of flow cytometry. Methods Mol. Biol. 91, 1-24 (1998).
  36. Mercer, A. C., Gaj, T., Sirk, S. J., Lamb, B. M., Barbas, C. F. 3rd Regulation of endogenous human gene expression by ligand-inducible TALE transcription factors. ACS Synth. Biol. 3, 723-730 (2014).
  37. Segal, D. J., Crotty, J. W., Bhakta, M. S., Barbas, C. F. 3rd, Horton, N. C. Structure of Aart, a designed six-finger zinc finger peptide, bound to DNA. J. Mol. Biol. 363, 405-421 (2006).

Comments

0 Comments


    Post a Question / Comment / Request

    You must be signed in to post a comment. Please or create an account.

    Video Stats